



14<sup>th</sup> August, 2021

To  
The General Manager-Listing  
Corporate Relationship Department  
BSE Limited, Ground Floor,  
P.J. Towers, Dalal Street, Mumbai.

Scrip Code: 524632

Dear Sir/Madam,

**SUB: - OUTCOME OF BOARD MEETING**

With reference to above subject and in compliance with the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e. 14<sup>th</sup> August, 2021 at 11:00 a.m. and concluded at 8.45 p.m.:-

- 1) Considered, adopted and approved Unaudited Financial Results for the quarter ended on 30<sup>th</sup> June, 2021.
- 2) Considered the day, date, time and venue for Annual General meeting along with record date of Register of Members & Share Transfer Books of the Company for the purpose of Annual General Meeting (AGM) of the Company.
- 3) Approval and adoption of notice for Annual General Meeting.
- 4) Approval and adoption of Director's Report and Secretarial Audit Report for the year ended March 31, 2021.
- 5) Appointment of M/s Soni and Patel, Chartered Accountant as internal auditor of the company for Financial Year 2021-22.
- 6) Appointment of Mrs. Rupal Patel, Practicing Company Secretary as Scrutinizer for the process of Remote E-voting as well as voting at the AGM

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully

**For Shukra Pharmaceuticals Limited**

*Bhoomi Patel*

**Bhoomi Patel**  
Director - DIN : 08316893

**CIN : L24231GJ1993PLC019079**



# SHUKRA

## PHARMACEUTICALS LTD.

### Financial results by company

PART I		(Rs. in Lakhs)			
Statement of Standalone Unaudited Results for the Quarter Ended 30/06/2021					
Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Previous year ended	
	(30/06/2021)	(31/03/2021)	(30/06/2020)	(31/03/2021)	
(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
<b>I Revenue from Operation</b>	296.21	426.19	110.89	1119.61	
<b>II Other income</b>	22.58	(15.25)	13.95	35.62	
<b>III Total Revenue (I + II)</b>	318.79	410.94	124.84	1155.23	
<b>IV Expenses</b>					
(a) Cost of materials consumed	76.11	176.13	35.21	294.70	
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	(38.07)	(44.14)	(19.26)	
(d) Employee benefits expense	103.95	163.49	58.02	406.74	
(e) Finance Cost	1.83	3.00	0.02	3.33	
(f) Depreciation and amortisation expense	36.84	38.74	36.21	147.37	
(g) Other expenses	95.11	79.01	37.65	293.04	
<b>Total expenses</b>	313.84	422.30	122.97	1125.92	
<b>V Profit / (Loss) before exceptional and extraordinary items and tax (III - IV)</b>	4.95	(11.36)	1.87	29.31	
<b>VI Exceptional items</b>	0.00	19.53	0.00	19.53	
<b>VII Profit / (Loss) before extraordinary items and tax (V - VI)</b>	4.95	(30.89)	1.87	9.78	
<b>VIII Extraordinary items</b>	0.00	0.00	0.00	0.00	
<b>IX Profit before tax (VII- VIII)</b>	4.95	(30.89)	1.87	9.78	
<b>X Tax expense - Provision for taxation</b>	1.24	(7.70)	0.00	6.40	
<b>XI Net Profit / (Loss) for the period (IX-X)</b>	3.71	(23.19)	1.87	3.38	
<b>XII Other Comprehensive Income</b>	0.00	0.00	0.00	0.00	
Items that will not be reclassified to Profit or Loss: Remeasurement of defined benefits plans (net of tax)					
<b>XIII Total Comprehensive Income) (after tax) for the period (9+10)</b>	3.71	(23.19)	1.87	3.38	
<b>XIV Paid up Equity Share Capital (Face value of Re. 10/- each)</b>	156.57	156.57	156.57	156.57	
<b>XV Other Equity excluding revaluation reserve</b>	1401.01	1400.47	1401.01	1400.47	
<b>XVI Earnings per equity share:</b>					
(1) Basic	0.24	(1.48)	0.12	0.22	
(2) Diluted	0.24	(1.48)	0.12	0.22	

**CIN : L24231GJ1993PLC019079**



# SHUKRA

PHARMACEUTICALS LTD.

**Notes:**

- 1 The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 14th August, 2021
- 2 The Audited Financial Statements are prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013 ("Act") read with Companies (Indian Accounting Standards) Rules, 2015 as amended and in the format as prescribed under Regulation 33 of the SEBI (LODR) Regulations, 2015. The financial information presented above is extracted from and is harmonized to conform with the Audited Financial Statements.
- 3 The Audited Financial Results of the Company are available on Company's website and also on the website of BSE Limited, i.e. www.bseindia.com, where the Shares of the Company are listed.
- 4 The figures of the quarter ended 30 JUNE 2021 are the balancing figures between Audited Figures in respect of the Full Financial year and the published year to date figures up to quarter June 30, 2021.
- 5 During the quarter ended 30 June, 2021, 0 complaints was received and attended.
- 6 Previous quarter's figures have been re-grouped / re-arranged wherever necessary.
- 7 The financial results for the quarter ended 30 June 2021 was reviewed by the predecessor auditor and they have issued unmodified conclusion on the same.
- 6 Previous quarter's figures have been re-grouped / re-arranged wherever necessary.
- 7 The financial results for the quarter ended 30 June 2021 was reviewed by the predecessor auditor and they have issued unmodified conclusion on the same.

**Date: 14/08/2021**

**Place: Ahmedabad**

**For and on behalf of the Board of Directors**

**Shukra Pharmaceuticals Limited**

*Bhoomi Patel*  
**Bhoomi Patel ( Director)**

**DIN: 08316893**

**CIN : L24231GJ1993PLC019079**



**The Limited Review Report**

**Review Report to Board of Directors  
Shukra Pharmaceuticals Limited**

We have reviewed the accompanying statement of unaudited financial results of Shukra Pharmaceuticals Limited for the quarter ended 30<sup>th</sup> June, 2021. This statement is responsibilities of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and Analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad  
Date: 14/08/2021



For, B J Trivedi & Associates,  
Chartered Accountants  
FRN-111042W

  
Bharat Trivedi  
Proprietor

M. No. 039595  
UDIN: 21039595AAAAER8677